Charles River Laboratories International, Inc. (NYSE: CRL), a provider of products and services for pharma companies to accelerate drug discovery...
Halozyme Therapeutics Inc. (NASDAQ: HALO) hit record revenue. Full-year 2025 revenue reached $1.4 billion. So this is 38% growth year-over-year....
Genmab A/S (Nasdaq: GMAB) released its full-year 2025 financial results, demonstrating the company’s improved operational execution. Total revenue reached $3.72...
Krystal Biotech, Inc. (NASDAQ: KRYS), a leader in redosable gene therapies, today announced record-breaking financial results for the fourth quarter...
Moderna, Inc. (NASDAQ: MRNA) has reported a narrower net loss for the fourth quarter of fiscal 2025, when the...
Moderna Inc. (NASDAQ: MRNA) reported fourth-quarter 2025 revenue of $678 million, a 30% decrease from $966 million in the same...
Executive summary Krystal Biotech has successfully transitioned into a commercial-stage biotechnology powerhouse following the landmark regulatory approval and rapid market...
Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, has reported a decline in adjusted earnings for the fourth quarter...
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues for the fourth quarter of...
Eli Lilly and Company (NYSE: LLY) on Monday said it signed an agreement to acquire Orna Therapeutics, Inc., a biotechnology...
